Merck puts $1B more into oncology, with kidney cancer a focus

Merck puts $1B more into oncology, with kidney cancer a focus

Source: 
Biopharma Dive
snippet: 

Merck & Co. is dropping just over $1 billion to acquire Peloton Therapeutics, a privately-held biotech working on small molecule medicines that target a protein which, when mutated, can foster tumor development.
Peloton's most advanced drug is under investigation as a treatment for kidney cancer.